Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial.

ABSTRACT:

Introduction

The α-glucosidase inhibitor acarbose is an efficacious medicine for the treatment and prevention of type 2 diabetes mellitus (T2DM). However, the response of gut microbiota to acarbose is important, as the microbiota may have a critical role in the development of metabolic diseases, and acarbose is metabolized exclusively within the gastrointestinal tract. We explored the changes in the proportion and diversity of gut microbiota before and after treatment with acarbose in patients with prediabetes.

Methods

We designed a randomized, double-blind, controlled crossover trial in which 52 Chinese patients with prediabetes by an oral glucose tolerance test (OGTT) with a BMI of 18-35 kg/m² were randomly allocated to treatment with acarbose or placebo. Gut mi

SUBMITTER: Zhang X 

PROVIDER: S-EPMC5380489 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature